Clinical Research Directory

Inclusion Criteria: Boys aged between 3 and 18 years (inclusive) diagnosed with C-CALD (elevated levels of VLCFA and leukodystrophy at brain MRI) * Boys or girls aged between 15 months and 18 years (inclusive) diagnosed with MLD (low ARSA activity and accumulation of sulfatides in urine) * Presymptomatic boys carrying ABCD1 mutations aged between 3 and 18 years (inclusive) (PRE-ALD) * Adult males or females aged between 18 and 60 diagnosed with MLD (low ARSA activity and accumulation of sulfatides in urine) * Males aged between 18 and 60 years diagnosed with AMN (elevated VLCFA and clinical symptoms of AMN without leukodystrophy at brain MRI) * Males aged between 18 and 60 years diagnosed with CALD (elevated VLCFA with leukodystrophy at brain MRI) * Adult males or females aged between 18 and 60 years diagnosed with ALSP (CSF1R mutation and leukodystrophy at brain MRI) * Presymptomatic patient adults (males or females) carrying CSF1R mutations (PRE-ALSP) * Children (15 months-18 years) without neurologic disease (no obvious neurological symptoms, normal neurologic examination) * Adults aged between 18 and 60 years without neurologic disease (no overt neurological symptoms) * Informed consent obtained : * from the parents or guardian for children patients and children controls; * from subject himself for adult patients and adult controls. Exclusion Criteria: * Participation to a therapeutic clinical trial * Treatment likely to modify the immune system * Unable to have a blood collection (i.e. low hemoglobin level at the investigator's judgment) * Any other reason, to the discretion of the investigator * Children or adults without health insurance or social security